What's in Autotelicbio's pipeline?

Autotelicbio has 5 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Autotelicbio's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/autotelicbio.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Autotelicbio — Portfolio Competitive Intelligence Brief

Autotelicbio pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ATB-1013	ATB-1013	phase 3	Autotaxin inhibitor	Autotaxin (ATX)	Immunology / Fibrosis
ATB-1012	ATB-1012	phase 3			Immunology
ATB-1011	ATB-1011	phase 3			Immunology

Therapeutic area mix

Immunology · 2
Immunology / Fibrosis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Autotelicbio:

Cite this brief

Drug Landscape (2026). Autotelicbio — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/autotelicbio. Accessed 2026-05-14.